Integrated Computational Design and Discovery of Novel Indole-Linked Guanidine Derivatives as BACE-1 Inhibitors for Alzheimer’s Disease
Journal of Computational Biophysics and Chemistry · 03.11.2026 · 1-36
DOI: 10.1142/s2737416526501152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Computational Biophysics and Chemistry, online erschienen am 03.11.2026. Verfasst von Pitam Ghosh und 6 weiteren Autor:innen.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is a chronic, progressive neurodegenerative disorder predominantly affecting 47 million people worldwide. Dysregulation of BACE-1, the initiating enzyme in the amyloidogenic cascade, plays a pivotal role in AD pathogenesis. Conventional anticholinesterase inhibitors can only provide symptomatic relief without stopping disease progression. In this study, we employed an integrated computational approach to rationally design novel indole-based BACE-1 inhibitors through pharmacophore modeling, 3D-QSAR analysis, ligand–protein docking, pharmacophore-guided virtual screening, MD simulation, and ADME studies. DDHRR_1 was identified as the best pharmacophore model with a survival score of 5.7767. Statistically significant 3D-QSAR models were obtained, wherein the atom-based model demonstrated high predictive reliability ([Formula: see text]), while the field-based model exhibited acceptable predictive ability ([Formula: see text]). Among the dataset compounds, compound B38 (3i) displayed the optimal binding affinity (−6.567 kcal/mol; PDB ID: 4DJU), with key interactions at GLY95, TYR132, and PHE169. [Formula: see text]-group enumeration generated 2408 derivatives, among which [Formula: see text]1 and [Formula: see text]2 exhibited strong binding affinity (−10.339 kcal/mol and −9.611 kcal/mol). A comparative analysis of the referenced ligand, the two best-performing ZINC-derived compounds (ZINC43707325 and ZINC03628223), and the two top-ranked [Formula: see text]-group compounds revealed that [Formula: see text]2 was the major lead compound. However, as these findings are based solely on in-silico analyses, further synthesis, biological evaluation, and BBB permeability studies are necessary to validate the therapeutic potential of [Formula: see text]2 against Alzheimer’s disease.
Zitieren
APA
Ghosh, P., Dhir, R., Sharma, D., Dhiman, S., Ali, A., Ali, A., & Asati, V. (2026). Integrated Computational Design and Discovery of Novel Indole-Linked Guanidine Derivatives as BACE-1 Inhibitors for Alzheimer’s Disease. Journal of Computational Biophysics and Chemistry, 1-36. https://doi.org/10.1142/s2737416526501152
Vancouver
Ghosh P, Dhir R, Sharma D, Dhiman S, Ali A, Ali A, et al. Integrated Computational Design and Discovery of Novel Indole-Linked Guanidine Derivatives as BACE-1 Inhibitors for Alzheimer’s Disease. Journal of Computational Biophysics and Chemistry. 2026:1-36. doi:10.1142/s2737416526501152
BibTeX
@article{Ghosh2026,
author = {Ghosh, Pitam and Dhir, Ryena and Sharma, Dinki and Dhiman, Shubam and Ali, Amena and Ali, Abuzer and Asati, Vivek},
title = {Integrated Computational Design and Discovery of Novel Indole-Linked Guanidine Derivatives as BACE-1 Inhibitors for Alzheimer’s Disease},
journal = {Journal of Computational Biophysics and Chemistry},
year = {2026},
pages = {1--36},
doi = {10.1142/s2737416526501152}
}
EUVIMED